Pfizer Inc.is stressing its commitment to the development of gene therapy for rare diseases by moving a Duchenne muscular dystrophy candidate into the clinic, after distancing itself from development of the portfolio it had built around allogeneic chimeric receptor T-cell (CAR-T) cellular therapies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?